Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diacerein + glucosamine sulfate + methylsulfonylmethane
- Development stage
- Unknown
- Lead developer
- Tabq Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Osteokonect is a fixed-dose combination pharmaceutical product developed by Tabq Therapeutics, primarily indicated for the management of osteoarthritis and joint-related pain. It contains three active ingredients: diacerein, glucosamine sulfate, and methylsulfonylmethane (MSM). Diacerein is an anthraquinone derivative that acts as a slow-acting symptomatic treatment for osteoarthritis by inhibiting the production and activity of interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine involved in cartilage degradation. Glucosamine sulfate is an amino sugar that serves as a precursor for the synthesis of glycosaminoglycans and proteoglycans, which are essential components of joint cartilage. Methylsulfonylmethane (MSM) is an organosulfur compound that provides a source of sulfur for connective tissue repair and exhibits anti-inflammatory and antioxidant properties. Together, these components aim to reduce joint inflammation, alleviate pain, and support the structural integrity of cartilage.
- Brand names
- Osteokonect
- Other names
- Osteokonect Tablet
02
Targets
IL-1R (Interleukin-1 receptor type 1 (IL-1R1))NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on diacerein + glucosamine sulfate + methylsulfonylmethane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diacerein + glucosamine sulfate + methylsulfonylmethane.